NCT04098575View on ClinicalTrials.gov

A Study Based on Data From German Registries That Looks at Characteristics of People Who Take the Medicine Empagliflozin for Type 2 Diabetes

CompletedOBSERVATIONAL
Enrollment

9,571

Participants

Timeline

Start Date

September 16, 2019

Primary Completion Date

December 31, 2019

Study Completion Date

December 31, 2019

Conditions
Diabetes Mellitus, Type 2
Interventions
DRUG

Empagliflozin

drug

Trial Locations (1)

15831

Diabetes Agenda 2010 GmbH, Mahlow

Sponsors
All Listed Sponsors
lead

Boehringer Ingelheim

INDUSTRY

NCT04098575 - A Study Based on Data From German Registries That Looks at Characteristics of People Who Take the Medicine Empagliflozin for Type 2 Diabetes | Biotech Hunter | Biotech Hunter